ブイフェンド静注用
Contents
1.2.
3. 3
4. 3 15 ALT GPT AST BUN GOT ALP y GTP LDH D FDP
5. Ca 1 1 AUC 1 7 C 2 2 AUC 3 2 HMG CoA
6. Q 2 HIV 1 HIV 2 C HCV B HBV T HTLV 1 HTLV 2 CMV EBV B19 B19 HIV 1 HIV 2 HTLV HHV 6 HHV 8 HBV HCV CMV EBV B19
7. 1 OR mr mr mm mr nm nm nm nm mm nm mr mr mm mm 1 200mg 1 2 3
8. 6
9. 10 1 12 13 150 10 2 1 2 3 4 5 6 7 8 9 10 11 12 13 14
10. sit ALT GPT AST BUN GOT ALP y GTP LDH D EDP 5
11. 1 4 2 6 10mgkg 2 G3 10mgkg 4 4
12. 30mL min 50mL min B SBECD 2 1 2 3 4 5 a Me ee
13. gt 15 3 mm 1 1 2 3
14. 10cm dish 4 5 223AABZX00034000 215008ZZ00294000 4 1 MCDB131 083m
15. QOL a 2 1 2 3 4
16. 5 gt NYHA V 35 gt 1 2
17. 3 eee 180 1 1 1 2 Child Pugh 4 C
18. 9 10 11
19. gt lkg 2 2 8 55 Pa 1 lkg 8 10mg 6mg 4 gt lkg Smg 1 2 6 8 gt
20. ES
21. 2 CPK 2 US DNA i 1
22. lt gt gt gt 20 1 2
23. i G C B D NR 5
24. 19 mL 2 10 1 4 5 nhgmL 4 5 ng mL
25. C 1 1 AUC 1 7 Ca 2 2 AUC 3 2 vito CYP3A4 7 CYP3A4 jn vitre CYP3A4 CYP3A4 8 0 AST GOT 7 0 ALP 7 0 ALT GPT 6 0 0 3 0 S 0 5 0 2
26. 2 a a ADH
27. 4 mL 6 mL 50 kg 10 4 PR partial response MR mixed response 1 2x106 kg 1 1 4 CR complete response 10 II IV GVHD 1 2x106 kg 1 2 4 4 GVHD GVHD
28. 2 gt 1 2 5 6 5 gt 1 1 2 4 G 8
29. 1 2 4 QT 1 0 QT torsades de pointes 3 0 6 1 0
30. BN 8 9 2 0 10
31. 8 jnfusion reaction G 9 3 3
32. 28 2 17 9 12 8 7 7 5 1 3 5 ee 6 2 8 383 1 Y
33. SH MN CYP3A
34. gt 1 1 2 3 3 8 9 es
35. QT torsades de pointes CYP2C9 5 4 gt lt CYP3A4 od RN 2 3 096
36. 1 400mg 1 2 1 1 3 1 1 610mg kg 1 3 1 1 400mg I 1 10mg kg 1 2 1 1 400mg 2 1 10mg kg 1 3 1 1 400mg 1
37. ON 3 infusion reaction infusion reaction infusion reaction 4
38. 5 6 1 10 mgkg 100 mg kg 2 1 2
39. gt 5 1 151 0072 2 44 1 TEL 0120 12 8195 151 0072 2 44 1 TEL 0120 12 8195
40. 14 14 2 13 gt gt lt Pe
41. voriconazole VRCZ 2A 35 2 2 4 difluoropheny1 3 5 fluoropyrimidin 4 yI 1 1 2 4 friazo 1 yl butan 2 ol CH NO 349 31 99 5 1 mol logD 1 69 pH7 4 1 2800mg 1 1 nfabunn L20050310037 2 nifabutin L20050310038 3 L20050310039 4
42. 2 3 1 1 2800mg 2800 mg 2
43. 13 14 94 AST GOT 15 QT Torsades de pointes i QT Torsades de pointes Sa 2
44. 5 1 0 1 6 1 2 7 1
45. ADH 1
46. 2 C 499 AUC 69 Ca 1 7 AUC 1 8 7 CYP3A4 CYP3A4 CYP2C9 vino HIV NNRTT
47. 4 5 6 SS 1 0 1 2 5
48. 103 8668 12 10 0120 566 587 9 00 17 30 T540 8645 AN 1 20 mg 1 Os 20 1
49. 4 3 2 1 2 1 1 10 8 mL 1 1 60373mg
50. EDQM TSE j TSE
51. 0 2 3 500 mm NN mL min
52. gt ta 42 9 377 42 9 3 7 4 3 7 1 3 28 6 2 7 PO 1 13 150C
53. 1 4 5 1 2 TNFc TNF ce
54. 6 1 2 3 7 1 37C 3
55. Ciprofloxacin JAN Ciprofloxacin INN CPFX 1 Cyclopropy1 6 f uoro 1 4 d1thydro 4 oxo 7 piperazin 1 y quino ine 3 carboxylic acid CsHiaFN 0 331 34 100 0 1mo1 L 99 5 1 2 3 4 5
56. _ ee C 93 96 AUC C 69 AUC 78 Cmax 3 0 AUC 4 3 Ca 619 AUC 77 C 1 4 AUC 1 4 C 669 AUC 82 QT torsades de pointes
57. CT CN 5 6 7 TNF
58. X CT 14 15 2 st 3
59. 16 3 7 6 25 01 38 1 1 in vitro 2 7 3 2
60. 15 30 3 mm 10096 Histamine dihydrochloride 2 1 Imidazol 4 y ethanamine dihydrochloride CH 2N 184 07 22N 2HC1 246 C LogP 0 70 1 2 2 8 C 3 6
61. 22 5mg 24 LH RH 872499 Tn SPRO 22 5mg 5 06 la 9 LEUPLINS PRO FOR INJECTION KIT 22 5 mg LH RH LH RH 1 II RH LH RH 2
62. 2 8 C 1 35 145 42 1 25 3 29 83 2
63. 9 396 31 335 6 0 21 349 2 8 10 9 1 2 3 4
64. C 49 6994 ATUC Caar 17 AUC 1 8 7 CYP3A4 CYP2C9 ypp CYP344 pp CYP3A4 NNRTIJ
65. 3 6 6 0 ee ee 1 Child Pugh A B 2 2
66. CYP3A CYP3A 7 em SBECD 1 3 mgkg 3 CYP2C19 2C9 3A4 CYP2C19 2C9 3A4 vipo CYP3A 1 62220 00 6 22 f 1 78
67. 1 1 GVHD JR 031 1 I JR 031 201 JR 031 202 2 GVHD JR 031 JR 031 301 3 JR 031 4 JR 031 5 JR 031 6 SCID Cr JR 031 2 J CR 659 0021 3 19 TEL 0797 32 3635 JCR 659 0021 3 19 TEL 0797 32 3635
68. 30 30 mL min 1 6 mg kg 1 2 3 mg kg 5 5 AUC Cmaxx SBECD 8 SBECD SBECD 30 50mL min AUCr C 1 5 4 4 SBECD 8 46 2 3 1 40 42 1
69. 150 1S0 150 307 602 309 604 608 9 48 9 16 3 7 6 25 0 109 223 80 239 1 180 100 86 2 Fleiss 12
70. 8 9 1600 mg 9 1 19mL 10 mgmL 0 5 5 mgmr S T1 T3 T3 G T4 F D 3 3 G KR
71. 3 22 5mg 81 45 55 6 17 39 14 81 13 6 11 81 6 2 5 81 6 2 5 81 6 29 5 81 22 5mg 83 77 92 8 50 6 42 83 43 4 36 83 28 9 24 83 18 1 15 83 16 9 14 83 15 7 13 83 14 5 12 83 14 59 12 83 13 3 11 83 12 0 10 83 12 09 10 83 10 8 9 83 8 4 7 83
72. 3 7 1 26 LVYEF 7 5 26 NYHA SAS 6 LVEF gt a 26 24 26 2 0 47 37 10 0 9 ie5 so ss 24 28 40 29 25 40 34 31 3 0 33 35 2 0 LVEF gt 1 4 C7
73. 3 5
74. 2 gt 1 Ty 2 GVHD gt 1 6mL 2 50kg
75. TSE 14 1
76. 2 10 3 7 7 5 1 4 5 1 20 5 y 12 8
77. 2mlL 1 1 JTE 350 2 Owen DA Poy E Woodward DF Daniel D Evaluation of the role of Histamine H and H receptors in cutaneous Inflammation In the guinea DPIg DrOduced by histamine and mast cell degranulation Br J Pharmacol 1980 Aug 69 615 23 103 8439 3 4 1 TEL 0120 316 834 FAX 03 3231 6890 105 8422 2 1 2 1 3 4 1
78. gt lt gt 10 1 3 A 5
79. 1 Smgkg ut infusion reaction 3 8 3 3 21 1 10mL UN 2 5 Se OT
80. 1 5 2 0 mii A 2 1 3
81. SBECD 1 16mgkg 1 2 2 1 3 mgkg 1 4mgikg 1 2 2 12 1 12 50kg 9mgkg 1 2 2 1 8 amp 1 mg kg 1 2 AN PH 1 mgkg 0 1 mgkg 200 mg BB 2 12 1 0kg 6mgkg 1 2 2 1 4 mgkg 1 2 1
82. 1 2 3 HIV HBV HCV HTLV 1 4 5 6 7 8 gt 1 2
83. 1 1 6 100 200 300 400 mg AUC C Ur Tr AUC ti 2 1 YE iL ugh ml ij 1 39 38 NS TO 483 32 A U9 A 15 D412 TD 6 3 LAD 1 8 11Qs 41 SS 131 SN 126 9 3141 1 62 119 Toul 6 CV 2 CYP2C19 CYP2C19 EM Extensive Metabolizer HEM Heterozygous Exfensive Metabolizer PM Poor Metabolizer 1 200 mg 1 2 1 400 mg 1 2
84. 5 1 65 2 1 2 bs 6 1 2 7 ee 3 ACE 8
85. gt 1 5 6 2 5 5 20xx xx XXXXXXXXXXXXXX 2 1 2
86. 1 1 2 2 1 2 LVAD 3
87. 2 3 8 m
88. 2 1 1 6 1 5 3 6 mgkg 0 89 2 11 4 53 ngmL 3 2 4 4 6 4 AUC 2 39 6 41 18 14 ng ymL 2 CYP2C19 CYE2C19 EM Extensive Metabolizer
89. B C 3 1 4 39 35 89 7 11 28 2 8 20 5 7 17 9 Y 5 12 8 1 1
90. 4 MR CT ca 5 6 7
91. 1 INR 8j jn vztro
92. Ur A A da H 22600AMX01311 2014 11 2014 2 201e s 2002 3 1 12 0kg 2 40kg 2 12 12 30kg 2 S00 mm
93. ES LH RH 1 1 LH RH 2 3
94. 6 1 10 mgkg 100 mgkg 2 7 1 2 2
95. 3 6 Se 2 GABA CR BUN
96. n 27 35 1 Smgkg 18 34 16 2 27 35 Cm 1 Cpre pr gmL 7 Smg kg 2 6 6 42 5mg kg 33 2 gmL 02 6 12 18 24 30 36 42 48 3 1 1 1 1 week 5mg kg n 32 33 1 Smgkg 740 4 33 696 4 48 n 32 33 7 01 37 Ci 1 Cpre gmL 8 5mg kg 2 6 31 8
97. 4 5 6 7 4 1 5 8 B C
98. 5 pe 2 6 10mgkg hd 3 TNF B 6 2 6 HBs HBc HBs B
99. 8 ME 2 a 2 CO 0 a 3 2 2 1 ER RS 1 CT 6mg i Ra
100. 1 L20030310030 30 I L20050310051 31 L20140813038 32 L20050310052 33 L20050310053 34 Lutsar L et al Clin Infect Dis 37 5 728 2003 L20040707110 35 Roffey S J et al Drug Metab Dispos 31 6 731 2003 L20040707072 36 Hyland R et al Drug Metab Dispos 31 5 540 2003 L20040707074 37 L20050310055 38 L20050310056 39 L20050310057 40 Herbrecht R et al N Engl J Med 347 6 408 2002 L20020909323 41 Perfec
101. 3 1 MCDB131 L DMSO 15 24
102. 2 1 LH RH 1 1 2 1 NSR i OM 2 iD 24
103. dmg kg th 49 3Omgikgtn 48 51 3mg7kg r 49 47 9 11 3 11 5 4 1 5 6 4 1 0 8 1 1 47 5 10 8 48 0 5 0 168 4 48 6 35 6 152 22 3 13 7 54 5 8 n 48 1 168 3 33 7 20 6 3 6 Cm 1 Cpre m 10mgkg 6mg 3mg kg 2 6 3mg kg 6mg kg 10mgkg 8 3mgkg 99 27 6mgks 104 24 10mgksg 104 13 Cm 1 Cpre a g mL 3 mg kg 6 mg kg 8 22 ACR 20 4
104. 2 1 1 2 3 3 P450 1A2 CYP1A2 1 5 kgz
105. L20070113007 20 Rengelshausen J et al Chn Pharmacol Ther 78 1 25 2005 L20050812016 21 L20041124004 22 HSCT FI L20150615074 23 SCT TFT L20150615075 24 L20150615076 25 yjyo L20030310046 26 ywo L20050310047 27 L20050310048 28 QTc IL20050310049 29
106. 4 gt Chid Pugh A 2 2 9 6 3 7 1 46 mL 40 mgmL 8 Nt 500 mm 180
107. ee 3 4 250mL 0 4 4mgmL 8 1 62 1 102 2 2 2 150 35 NYHA III TV 5 10mg kg 2 6 3
108. 2 MTCs 0 39 3 13g g mL MIC 0 025 1 56 g mL 2 2 EDi 1 14 1 6 2 IN 4 MIC 0 08g m 24 30 10 9 3 8 9 1 6 9 DNA DNA
109. L20050310056 41 L200503100571 42 Herbrecht R et al N Engl J Med 347 6 408 2002 L20020909325 43 Perfect J R et al Clin Infect Dis 36 9 1122 2003 L20040707126 44 L20050310038 45 yzo vio L20041124005 46 yjyo L20050310059 47 i vivo L20050310060 48 yo L20050310061 49 Candida yzvo L20050310062 50 Candida
110. mh mh umh mmm mmm immm mm mh mm mm im mm mm hm mm mm im mm im im mm immm mm mi mem rm immr immm mm mm mm mmm rmr mh lm rm mm im em mr mr mm mem rm mm mmm mmrem mh mm nm mmm nm mm nm mm nm mv nm mm nm rm mm 24 1 22 5mg 1 A AE J F gt 24 24 ON 24 1 1
111. 10mg kg 28 10mg kg 3 5mg kg 1 10mg kg 51 11 5mg kg 50 3 49 5 1 10mg kg 8 5mg kg 4 3 TNF oc TNF a 4 10mgykg 3mgkg
112. 0 22 1 0 0 46 2 58 4 9 7 ypo CYP2C19 CYP2C9 CYP3A4 N 5 96 2 6 1 1 200 mg 1 2 1 400 mg 1 2 Child Pugh B 1 100 mg 2 1 200 mg 1 2 AUC 2 6
113. Re 3 0 1 5 0 1 5 2 59 0 1 5 LDH AST GOT ALT Ea GPT GTP AL P 1 0 1 4 i 1 3 2 3 6 8 a 9
114. 201 269 200mg VFENDS for Intravenous Use 2014 10 14 7 21700AMY00173 200 6 2005 6 2 201 2002 3 2 1 pH 5 7 0 19 mL 10 mg mL 2
115. 3 4 3 TI 7 3 3 2 1 1 1
116. 2 30 1 3 1 kg 1 2x106 1 18 mL 4 mL 1 2 3 4 1 1 4 90 3
117. 200mg 24 1 1 1 2 3 4 5 6 7 QT QT
118. 3 22 7 3 100 1 100 mg 5 gt 1kg 3mg 1 2 6 8 6 1 1kg 8 10mg 6mg 4 gt ikg 5mg 1
119. Ia CYP3A4 CYP3A4 CYP3A4 CYP2Cl9 CYP2C9 CYP3A4 CYP2C19 CYP2C9 CYP3A4 CYP3A4 CYP3A4 CYP3A4 2 HIV
120. 2 Rh Cmax 7 AUC 10 oo GABA MG CR 0 a SCA 2 0 0022 200 2 EE Cmax 17 AUC 229 6 0 0
121. 2 8 1600 mg 9 1 46 mL 40 mg mL 2 2 1
122. C 14 AUC 46 7 C 36 AUC 61 Ca 15 AUC 53 AUC 59 CYP3A4 mn vg CYP3A4 Im po CYP3A4 CYP3A4 m wp CYP3A4 CYP3A4 CYP2C9 CYP2C19 CYP3A4
123. MMP vztro PDGF 1 1GF 1 MMP 4 co MHC 1 MHC 1 IFN Y MHC Ti IFN y T CD40 CD80 CD86 IFN Y 95 PGEs IDO
124. 5mgkg 2 6 6 24 48 ASAS Assessment in Ankylosing Spondylitis 20 97 0 32733 96 9 31732 2 lt ASSERT 3mgkg 2 6 6 24 ASAS 20 19 2 15 78 61 2 123 201 p lt 0 001 6 1 208 Smg kg 2 6 8 22 30
125. 200 mg 1 2 7 Ca AUC 34 24 58 37 T 1 4 1 5 4 6 A 4 6 Lkg 1 1 10 0 22 1 0 0 46 2 58 7 5 9 Yo CYP2C19 CYP2C9 CYP3A4 N 96
126. mm mm um am am mm mm mm mm EE 1 1 2 Child Pugh C 3 4 2 1 2 3 4 5 6 ae Me Me em a
127. 2 19 mL 10 mgzmL 2342 3 a 1
128. TSE 000 3 gt 1 022 889 87 0 23 5 10 7 8 8 1 5 1 AL
129. 3 mg kg 3 35 0 83 10 46 6 mg kg 7 19 1 27 21 62 ru g mL 327 5104 NONMEM version VI 4 ATTRACT 12 5mg 3 10mg kg 2 6 4 8 102 3mgkg 4 73 10 3mgkg 8 71 8 10mgkg 4 74 1 10mgkg 8 77 6 5
130. Ca 3 0 AUC 4 3 C 619 AUC 77 7 C 1 4 AUC 14 EF Cam 66 AUC 82 3 QT torsades de pomtes
131. 4244 60 341 No 1501001 150 307 602 309 604 608 3 35 61 162 248 162 248 57 4 65 3 14 18 27 39 67 119 69 2 56 3 No i 1501001 MM 150 150 307 602 309 604 608 8 8 1 1 100 a 2 2 2 EE 8 45 5
132. pH 3 9 4 5 24 5 30 6 10 1 750mg 2 tz AUC 3 27m vitro DNA
133. 5 17 100 41 41 100 43 43 1 FEV 12 3 16 4 29 1 zn vztro Enterobacter cloacae
134. E Ca 93 AUC 96 Ca 699 AUC CYP3A4 CYP3A4 CYP3A4 CYP2C19 CYP2C9 CYP3A4 CYP2C19 CYP2C9 CYP3A4 CYP3A4 CYP344
135. 3 762 901 24 0 2 8 2 2 1 7 Q 5 1 3 337 103 8 5 6 3 1 1 1 1 p BR er 2 2 1 1
136. 11 25mg 12 1 4 9 4 4 48 30pg mL 22 5mg 97 6 81 83 11 25mg 96 49 81 84 95 1 2 5 2 7 896 95 10 1 LH RH LH RH LH LH RH 100
137. CYP3A 3 CYP2C19 2C9 3A4 CYP2C19 2C9 3A4 in vitro CYP3A 5 22E
138. 2 3 4 3 6 4 0 8 3 6 16mg kg 4 1 0 6 1 5 4mg kg 2 22 5mg ngf mL 10 o 4 PP TT T T T T T
139. Cmax AUC AUCg 24 t CLtot CLr 7 7 2 mg L mg hr L mgrhr T hr IL hr kg L hr kg Ccr gt 90 3 80 10 2 32 5 4 59 0 45 0 234 400we 0 9 61 Ccr 90 4 59 15 4 50 4 5 23 0 33 0 138 400mg 8 1 9 400mg 12 1 28 26 24 13 20 47 300mg 12 0 21 28 29 30 26 86 a min 1 73m b p 0 05 vs Ccr gt 90 group c AUC X Ccr 24 CLr 7 400mg 2 1 10
140. 10 7 _3 28 1 1 vitro 2 7 3 2 voriconazole VRCZ 2R 3S 2 2 4 difHHuorophenyD 3 3 fluoropyrimidin 4 y1 1 1 2 4 triazol 1 yl butan 2 ol
141. gt 20XX X 2X 2014 10 CiproxanW I V 200 2 3 4 5 js 1 100ml 200mg 200mg
142. 2 i CT 3 Diniusion reaction 2 inf
143. a 0 om lb NA 9 1 09 e 9 b o20 4085 8 NA a o b a 3 b NIH SEER database 2 52 37 30 13 61 10 2 a ie6 0 046 Il 6 NA lt 1604 1O 36 G g b
144. 5mgkg 2 6 8 62 Smgkg 3 8 Smg kg 2 6 8 46 14 34 8 0 39 ggmL 2 27gmL Smg kg 64 19 8 4 4 P J Y Z 4 1 r 4 D r gymL 02 6 10 14 18 22 26 30 34 38 42 46 50 54 58 62 66 70 1 1 week 5mg kg
145. 10 Smgkg 2 6 8 46 35mgkg 18 1009 8 i 5 h 0 0 1 30 40 St tf 1 5 1 n 7 11 n 2 3 n 3 4 a 2722 104 55 Ci 1 Cpre
146. 53 303 162 248 65 3 65 3 Se 27239 67119 406 56 3 100 74 5 56 3 45 6 2 9s 19 No
147. Cmax 609 AUC 849 QT QT 1A 2
148. LH RH LH RH LH RH 753 LH RH 1 2 1 24 1 2 24 1 NN 6 H HSe rp Se yD A TO CH H C COH
149. 2 6 8 gt lkg Smg 1 2 6 8 gt 1kg Smg 1 2 6 6 8 gt tkg Smg 1 2 6 8 1kg 10mg 1 lt gt 1kg Smg 1 2 6 8 6 1kg 10mg 1
150. 22 5mg 24 1 2 SR 11 25 mg 22 5mg 24 1 2 11 25mg 12 1 4 F 48 100ng dL 22 5mg 100 81 81 11 25mg 98 7 78 79 95 1 3 3 4 6 896 95 10 22 5mg 24 1 2
151. CYP2C19 S 1 An 9 C 14 6 AUC 46 9 2 0 St John s Worr Cg 369 AUC 61 Cr 15 AUC 53 AUC 3 99 CYP3A4 CYP3A4
152. 2 3 GVHD 1 1 T 201 202 IL 301 14 201 202 GVHD 1 II IIV GVHD 1II IV a 18 2 30 1 100 200 mg 5 10 mg 3
153. 2 1 ImL InL ue 50mg 5mg 80 Img im pH 6 0 7 0 1 gt i i i i i i i i 1 i a
154. a 63 9 1i29 aj 3 b NIH SEER database 3 5 105 18 106 1946 15 3 e a o b a 3 5 b NIH SEER database 1 vitro TNF e
155. In 3 In C Tn 111 iR 111 90 110 CIn a 1 In 1 2 1 pH 1 5 1 9 1 28 5
156. 10 3 1 1 2 3 2 1
157. B B 10mg kg Smg kg 8 i B 8 me i 12 2 6 4 8
158. St Johns Wor 1 9 0 C s 2 2 AUC 3 8 AUC C z 1 2 AUC 1 5 Ca 30 79 AUC 47 2 Cmax AUC AUC 9 Cx AUC 17 1
159. Vd 1796 Smg kg 20 2 Smg kg 2 6 AST GOT ALT GPT 3mgkg 31 1 2 0 1 6 2 0 gp 3 1 5mgikg n 28 30 10mgkg n 29 32 Smg kg 168 33 7 21 8 5 4 28 1 113 206 26 746 4 13 8 33 3 14 10 6 EE
160. 1 200 400mg 1 400ng 79 1 400mg 1 2 1 3 3 6 9 LE mL 100 300mg 1 2 400mg 1 3 12 hr AUC ss CmaX SS t 2 SS 25 8 23 4 8 07 22 5 2 44 8 10 22 2 28 8 8 14 24 1 3 00 4 54
161. B 6 1 1 2 3 4
162. 2 8 C 3 20r 20 Histamine dihydrochloride 10mg mL 1 1 2 mL 20 mg 50 v v 0 51 w v pH 1
163. TNEFo tumor necrosis factor o 201e 2 8C 201 1998 8 TNFa 100 REMICADE for ILV Infusion100
164. x 46 60 67 119 85 174 162 248 76 7 36 3 48 9 65 3 2 93 48 9 33 5 109 7223 80 239 1 180 100 86 2 Fleiss
165. Cmax AUCoa AUC AUC tz Vss CLtot CLr Cd 44 41 56 50 68 22 56 169 85 5 71 34 6 38 4 7 65 111 41160 4110 410 11 1 2 44 CLd dialysate clearance AUC mg kg AUC 7 1 4 2 3 4 13 26 2 ERc
166. 1 1 2 25 1 3 10mgkg 5mgkg IOIBD 4 2 1 4 CDAI 4 70 4 3 6 Smgkg 2 6 10 CDAI 25 70 et 57 6 8 46 4 50 54 82 596 47 57 CDAI 150 61 49 4 TR 5mgkg 8 39 10mg kg 8 32
167. 6mg 3mg kg 2 6 14 ACR 20 23 49 11 47 61 2 30 49 0 001 3mg kg 8 4 34 8 ACR 20 53 3 24 45 6mg 3mg kg 2 6 3mg kg 6mg kg 10mg kg 8 54 ACR N SD 3mg kg 99 51 3 32 1 6mg kg 104 53 8 34 4 10mg kg 104 58 3 31 3 10mg kg 3mg kg
168. 9 1000 15cm Tn 19 2 Ge 111 0 3 Tn 25 83 1 3 1 3 4 4 27 27 a 28 lIn 28 0C 1 n _ 29 PTn 30 44 29 43 1
169. 1 300mg 1 2 2 1 150mg 1 200mg 1 2 1 400 mg 1 2 2 1 300mg 1 2 40kg 100mg 1 2 2 1 150mg 1 2 1 9mgkg 1 2 1 mgkg 1mgkg 350mg 50mg 1 350mg 1 2 1 300mg 1 2
170. 30 54 59 6 11 30 MR1 IL 6 MRI IL 6 33 3 173 30 PET CT CRP ESR 100 0 4 4 Smg kg 8 3 10mg kg 8
171. 300mg Cmax 1 2 AUC 0 9 82 594 300mg 200mg 2DOmeg 8D B 5 9G 2 4 6 10 12 f8 CmaX maX ti tag CLtot AUC 1 71 0 98 0 58 3 40 3 We 0 0 2 039 1 41 0 98 0 61 3 49 5 42 0 08 ealaeelae2 5 200mg 2 06 1 50 0 24 3 89 30 6 6 60 90 0 07 0 00 0 05 0 17 1 3 0 1 300mg 70 76 1 200mg 1 1 1 1 1 300mg 1 1 2 4 AUC CLtot Cmax Vss 9 11 trz tzg Cmax Vc Vss CLtot AUC
172. 8 et 53 2 3 4 2 2 1 2 500mg 80 0 5mg 2 2mg 6 Img pH
173. 8 Mayo 35 6 37 104 54 8 7 104 p 0 005 2 lt ACT1 gt 242 Smgkg 2 6 8 46 54 8 Mayo 37 29 45 121 69 4 84 121 p lt 0 001 7 5mgkg 2 6 8 46
174. 2 8 1 2 1
175. 2 1 1 200 mg 1 2 1 400 mg 1 2 Child Pugh B 1 100 mg 1 2 1 200 mg 1 2 AUC 2 6 2 30 50 mL min 1 6 mgkg 1 2 3 mgkg 3 5 AUC C 3 4 8 1
176. 8 3 5 169 1 3 NIH SEER National Institute of Health NIH Surveillance Epidemiology and End Results SEER dafabase 1 14 49 21 0 20 1 1
177. 8 10mgks CDAI 95 0 103 5 87 2 33 40 95 0 109 7 98 8 _ 11 26 2 NN Smg kg 4 CDAI 70 17 4 24 Smgkg 81 22 27 Smg kg 2 CDAI 25 70 2 6 8 46 Smg kg 10mgkg p 0 002 19
178. i NT 5 RYANiee tr Ne A Es 8 D 4 6 AST GOT ALT GPT GTP LDH i 7 3 i 8
179. yivo L20050310063 51 Candida non albicans yo L20050310064 2 Cryptococcus mvivo L20050310065 53 Cryptococcus yivo L20050310066 54 vivo L20050310067 55 yo L20030310068 56 rjpo L200503100691 131 8389 3 22 7 0120 664 467 FAX 03 3379 3033
180. 5 6 60 CDC rm mm mm mm mm nm mm mmnmrmm mm am mmm 2 6 mL min 1 200mg 12 1 200mg 24 400mg mL min kg x 140 72X mg dL 0 85 10
181. 1 3 1 1 400mg 2 1 10mgkg 1 3 1 1 400mg 1 2
182. 4 2 30 3 4 5 6 30
183. 900mg 0 99 1 10 1 2 EE A EE A A A a OE FF EE EE EE EF A Ee EE EE i i i Er i rr rE 1 876
184. 10 5 BUN ee a 3 PE 0 1 1 3 4 5 7 AST GOT ALT GPT BN AL P LDH GTP 3 11
185. CHL 4 TA104 V79 1 200 300mg 1 ET 10 0Dmg 5 20mg 3 24 09 4 8 6 122 tu CmaX Vc Vss CLtot AUCO_ ea 0 20 3 5 2 53 29 1 117 3 30 3 6 66 8 0 01 0 3 0 16 2 1 16 0 3 2 0 73 0 12 2 6 3 33 23 3 111 8 41 5 7 49 5 0 03 0 3 0 55 7 4 21 8 9 3 1 39 t Cmax Vc Vss CLtot AUC
186. 10 11 21 24 4 100 80 80 0 23 0 24 0 Y GTP 11 0 8 0 8 0 8 0 12 CK CPK 13
187. 53 6 149 278 7 6 6 5 8 5 0 5 0 1 1 2 Toxic Epidermal Necrolysis TEN 1 9 CYP2C9 Stevens Johnson i 5 9 lt C 2 2 AUC CYP2Cl19 CYP3A4
188. 2 3 MS W 1 1 2 2 2 6 infusion reaction
189. 114 36 8 59 4 53 6 72 3 98 ru gmL i16 05 29 09 Cm 1 Cpre 10 6 86 327 8 18 Cg 1 Cpre 5mgykg 8 3 10mgkg 10mgkg 3 8 Cu 16 mm1 Fl Cm 1 Cpre gmL a 10mgkg 0 2 TNFa sg 10mg kg 6 23 7 IgG
190. 2 HBSS a 800mLx2 98ml 1 HBSSG 50OmL2 3 2 3 3
191. 7 29 6 83 6 0 5 83 QT 6 09 5 83 6 0 5 83 6 0 5 83 6 0 5 83 6 096 5 83 2 4 12 1 1 X 0 1 2 0 1 3 AST GOT ALT GPT
192. 2015 10 45 11 923 1997 11 45 10 846 1997 12 45 11 936 1997 13 Bergan T Diag Microbiol Infect Dis 13 103 1990 14 31 7 2503 1997 15 Ra jagopalan P et al 2003 16 Shah A et al 7 Antimicrob Chemother 38 103 1996 17 Hogan C et al 1993 18 15 4 337 1995 19 45 11 901 1997 20 Church D A et al 1995 21 1997 22 1994 23 1997 24 Saito A et a1 7 Antimicrob Chemother 18 251 1986 25 jpn Antibiotics 61 241 2008 26 Takesue Y et al Infect Chemother 18 816 2012 27
193. L20050310040 5 Purkins L et al Br J Clin Pharmacol 56 SupplL1 37 2003 L20040707053 6 HIV PE450 yzo IL20050310041 7 CYP3A4 P450 im jo L20050310042 8 Romero A J et al Clin Pharmacol Ther 71 4 226 2002 L20040707176 9 IL20050310043 10 Purkins L et al Br J Clin Pharmacol 56 Suppl 1 24 2003 L20040707054 11 L20050310044 12 P450 vimo L20050310045 13 Saari T F et al Eur J Clin Pharmacol 63 10 941 2007 L20071002034 14 Saari T Let al Br J Clin Pharmacol 63 1 116 2007 L20070313251 15 Hagelberg N M et al Eur J Clin Pharmacol 65 3 263 2009 L20090225001 16 Saan T Let al Eur Ff Clin Pharmacol 64 1 25 2008 L20080117022 17 Hynninen V V et al Antimicrob Agents Chemother 50 6 1967 2006 L200
194. nm wo CYP3A4 CYP3A4 CYP2C19 CYP3A4 CYP2C9 CYP2C9 CYP3A4 CYP2C9 CYP2C19 CYP3A4 CYP3A4 4 21 24 100 80 80 0 25 0 24 09 y TP 11 0 8 0 8 0 8 0 8 0 AST GOT 7 0 ALP 7 0 ALT GPT 6 0 0 0
195. 3 9 0 4 0 1 3 3 3 4 6 8 9 10 8 8 31 33 48 51 90 0 100 93 9 94 1 83 3 83 8 3 0 2 11 12 14 18 6 8 2 2 13 1 21 27 0 a 5 8 II 198 234 06 3 3 3 3 3 78 69 22 28 90 09 18 20 68 8 11 16 92 3 12 13 4 5 57 1 4 7 87 5
196. 5 23 59 0 7 17 9 9 23 1 8 20 5 31 79 5 HLA 17 43 6 22 56 4 6 8 9 8 14 9 12 8 4 15 13 8 8 1 7 I HI 201 202 4 CR PR 14 18 92 9 24 14 9 64 3 8 I 301 24 28 CR 25 12 48 0 95
197. p 0 024 10 ACR 20 54 ACR 20 3mg kg 37 5 9 24 6mg kg 61 5 16 26 10mg ks 61 5 16 26 X Sharp Score 1 3mgykg 0 00 6mgykg 0 48 10mgkg 0 00 2 ATTRACT gt 12 5mg 3mgkg 2 6 8 34 54 ACR 209 MTX 17 0 13788 41 9 36 86 p 0 001 34
198. hr hr pg mL 1 DD OU hr pg hr mL EE ED ET 300mg 1 75 071136 313 1735 i088 244 1231 30kgg 100mL min 0 60L h kg 2 16L kg Ccr Cer gt 90 10 61 Ccr 90 11 31 Ccr 60 11 Ccr 30 10 4 1 400mg 300mg 8 12 2
199. 4 1 2 P0
200. T T GVHD MHC I II 51Cr SCID 2 24 72 336 672
201. 26 0 27 0 30 6 31 0 33 1 4 1 8 9 7 4 6 3 5 5 95 CT 21 0 16 0 23 0 23 0 26 0 33 0 37 0 43 0 41 0 42 0 27 0 280 290 s0 0 320 22 1 7 1 14 2 33 9 L 20 7 SAS METs 13 26 6 gt peak VO m mL kg min mL kg min 8 08 28 26 O 485 520 19 4 16 5 10 5 8 6 400 0 204 21 its 8 9 285 292 78 sa 640 530 11 145 8 3 11 sn s97 EE EE BE DE EE 410 1 455 4 13 4 14 6 8 7 9 3 136 1 103 7 5 3 4 9 2 3 2 2 95 CI 257 4 339 1 6 5 6 9 5 7 5 9 562 9 571 7 20 2 22 3 11 7 12 6 400 0 780 jis 1 02 se 2 26 3 3 2 2 1 1
202. 3 0 5 0 2 53 6 149 278 7 6 6 5 8 50 5 0 1 1 2 Toxic Epidermal Necrolysis TEN Stevens Johnson 3 3 0
203. O Leuprorelin Acetate JANJ 5 0xo L proly1 L histidy1 L tryptophy1 L sery L tyrosyl D leucyl L leucyl L arginyl ethyl L prolinamide monoacetate CssHsaNieOiz CzH4O2 1269 45 100 99 5 1 1 18 Supp1 3 589 609 625 633 1990 2 18 Supp1 3 575 1990 3 41 587 2014 4 3 5 3 6 18 Supp1 3 515 1990 7 18 2615 1990 8 36 64 1977 9 18 Supp1 3 521 1990
204. X 2 6 7 8 AST
205. lkg 5mg 1 2 6 8 gt 1kg Smg 1 2 6 6 8 gt lkg Smg 1 2 8 2 1 6 lkg
206. 1000L 50mL 6 Casein PR lt gt NYHA V 35 gt 1
207. 54 19 20737 ACR 20 83 3 10 12 37 1 4 7 87 5 7 8 2 IMPACT2 9 gt 5 CRP 1 5mg dL 45 5mgkg 2 6 8 46 14 ACR 20 11 0 11 100 58 0 58 100 0 001 X Modified Sharp Score 24 0 82 2 62 0 70 2 53 p lt 0 001 5 1
208. 5mgkg 10mgkg 38 p 0 002 54 p lt 0 001 3 Smg kg 3 2 6 2 26 831 5mg kg 689 21731 Smgkg 2 6 10 14 8 46 Smgkg 14 14 3mgkg 40 S5mgkg p lt 0 001 2 1
209. BUN 12 LDL 3 i EE n 3 3 4 LH RH 5 1 2 1
210. CT CT 1 a
211. CaHi4F N O 349 31 99 5 1 mol logD 1 69 pH7 4 1 200mg 10 1 nfabunn L20050310037 2 nfabutnn L20050310038 3 L20050310039 4 L20050310040 Purkins L et al Br J Clin Pharmacol 56 Suppl 1 37 2
212. EBM HEM 2 PM 3 HEM PN U fg7m 7 3 3 14 18 1 8 mg kg 1 2 1 9 mg kg 1 2 7 1 9 mgkg 1 2 7 C AUC 7 22 2 03 18 3 ngmL 4S 8 10 0 156 ug MmL CYP2C19 Cmax AUC Taax pg mL ugrh mL V b EM 6 5 49 2 03 11 0 312 10 0 80 8 15 0 93 3 8 HEM 10 7 66 4 45 18 3 49 3 14 5 156 11 0 92 2 2 PM 2 12 3 11 6 13 0 99 1 84 0 117 10 0 95 1 1 18 7 22 2 03 18 3 45 8 10 0 156 1 0 0 92 3 8 1 2 12 15 50 kg 1
213. XX Sharp Score 4 00 0 50 p 0 001 54 ADL HAQ 0 1 0 3 p lt 0 001 QOL SF 36 0 6 1 2 p 0 002 3 1 Smg kg 2 6 14 SD 10 17 10 60 0 66 0 98 p lt 0 001
214. 22 5mg kg TP 104 10 E1000 rE gt 100 NN t0 N 01 3 0 2 5 8 iQ 14 18 2 3D t f 1 1 1 waeki 5mg kg n 62 104 1 gt gt i ss 0 C 30 20 0 C 14 22 20 Cpre Cpre e Cpre Cpre mgkg rr62 95 88 11 09t 345 252 2 46t 21 50 7 19 3 98 2 73 79 93 72 10 88 2 31 1 46 1 46 Cin 1 Cpre p mL 9 ACT1 5mg kg 2 6 8 46 5mg kg 116 9
215. 004m _ 003m DMSO om 0 5 w w rab a 20 wv HBSSG HBSS O WBss 50 0 16g 5 10cm disb N 3 5cm dish N 10mL 225mL 250mL 200gL
216. 10mgkg 359 5 75 1 50 6 17 6 n 29 274419 54 1 93 7 31 7 69 1 9 3 23 6 32 Cip 1 Cpre gmL 3 6mg 3 10mg kg 2 6 BMI 3mgkg 49 2 10mg kg 50 4 E 1009 109 Sv A 0 N A 1 ww Ri1 4 g 8 10 12 14 1 1 week 1 KG6Hg 3
217. Smgkg 8 5mg kg 8 0 30 g gmL 10mg kg 10mgks 8 129pgP 10000 1060 gymL week 5 mg kg 8 10mgkg n 26 39 0 16 1 1 Cis 1 Cpre 2 Smgkg Cmax 118 g gmL vd 3 0L 9 S
218. 2 6 8 3 1 2 4 RN 6 1 1I i0mL 6 3 250mL 7
219. TNF gt 8 10 1 infusion reacton 11 dsDNA M ds
220. 5 1 1 5mgkg 3 0 2 6 10 14 8 8 E 10000 1000 ea 100 No 2 2 NN 30 1 week 5mgkg 8 mF31 38 0 22 46 1 1 14 e 30 2 26 80 4 16 9 3 1H24 262 1 78 9 3 1 Cm 1 Cpre z gmL
221. QTc L20050310049 29 1 L20050317019 30 1 IL20030317020 31 L20140813038 32 L200503100321 33 L20050310053 34 L20140815039 35 20050310034 36 Lutsar I et al Clin Infect Dis 37 728 2003 L20040707110 37 Roffey S J et al Drmg Metab Dispos 31 6 731 2003 L20040707072 38 Hyland R et al Drug Metab Dispos 31 5 340 2003 L20040707074 39 L20050310055 40
222. Y 6 7 200mng 100mL X10 1 Cockcroft D W et al Nephron 16 31 1976 2 20 17 8903 1986 3 Roberge R J et al Ann Emerg Med 36 2 160 2000 4 Cyrus P 2003 5 31 2433 1997 6 31 8 2701 1997 7 Rogge M C et a1 300 400mg 1990 age Er 8 Lettieri J T et a1 200 400mg 990 9 Sampson Landers C
223. hemotherapy 42 140 1996 28 Friedlander A M et al1 Inf sg 167 1239 1993 29 Chemotherapy 33 S 7 1 1985 26 30 TEL 0120 121210 FAX 03 6418 3880 26 30 4 9 CC mo MP 2 1 22 5mg mL 4 1 22 5mg s
224. lt gt lIkg 5Smg 1 2 6 8 1 2
225. 11 12 CK CPK 13 X CT 14 15
226. 3 30 2 a 10 1 4 5 ngmL 4 5 ngmL 2
227. Cu 30 7264 AUC 47 2 i 6 1 0 1 Ce AD AUC 9 7 C AUC CYP2C9 A 8
228. 1 2 2 3 _ 8 4 4 1 27 1 27 28 Tn 28 In 29 Tp 30 44 GVHD 1 kg 1 2X10 1 18mL 4mL 1 2 3 4 1 1
229. 1 4 mg kg 2 1 6mgkg 1 2 7 1 200 mg 1 2 7 CYP2C19 EM CYP2C19 1 1 CYP2C19 1 17 HEM CYP2C19 1 2 CYP2C19 1 3 PM CYP2C19 2 2 CYP2C19 2 3 CYP2C19 3 3 2 co 96 100 200 mg 40 mgmL 1 200 mg 1 2 1 400 mg 1 2 7 200 mg 1000 kcal
230. 14 12 11 7 4 1 10 PASI Psoriasis Area and Severity Index 12 Smg kg 2 6 10 PASI 75 0 0 0 19 68 6 24 35 p lt 0 001 10 PASI 12 5 CRP 1 5mgdL 45 Smg kg 2 6 8 46 PASI 759
231. VEP 4 4 80mg kg 26 20 40mg kg 4 30mg kg 13 18mg kg 26 20mg kg 4 20mg kg 30mg kg 10mg kg 5 UVA 100mg kg 6 jn ztro 200p g mL 1 1 1 200mg 1 2 3 1 300mg 1 2
232. 10mg 1 2 gt 1kg Smg 1 1 2 6 8 1 6 kg 10mg 1 2 lt gt 1kg Smg 1
233. 5 10mg kg 2 6 8 46 10mgkg 8 3mgkg 57 77 60 82 0 85 090 n 86 14 23 13 60 098 1 13 99 58 14 60 35 0 50 044 6mgkg 388e 110 94 2 18 2 88 n 91 11 74 23 83 2 30 2 80 10 58 52 113 41 1 81 228 10mgkg 5823 188 70 4 73 6 50t r 95 11 34 39 61 4 78 626 104 57 16 186 12 3 13 5 47 090 1 R S fn N AS i 91 Na 02 8 14 30 38 45 5 54 tt 1 1 1 weaeki Cin 1 Cpre mL 6
234. 1 300mg 1 M1 N M2 M3 3 1 8 4 8 7 3 1 300mg 1 24 58 1 Ml 1 0 M2 2 6 M3 4 69 66 39 20 22 6 200mg 90 200mg 300mg 100mg 2 3 200mg 200mg 1 5 Cmax 200mg AUC 1 2 200mg
235. 27 8 68 7 4 CR PR 25 15 60 0 38 7 78 9 52 25 12 2 24 23 2 1 CD3 CD28 T Ez PGE2 2 3 IDO IDO1 y IFN y Toll TLR 3 TLR4 CD4 T 3 2 qa4 81 CXCR4
236. 4 201X XX 1 HS 1
237. 7 8 80 8 21 26 1 300mg 1 2g 1 2 ie 85 7 78 91 84 0 63 75 78 99 30 38 100 28 28 58 39 7 12 100 8 8 200mg 1 2 3 300mg 1 2 TL 40 6 13 32 2 1 400mg 1 2 3 400mg
238. HEM Heterozygous Extensive Metabolizer PM Poor Metabolizer 6 mgkg 1 2 3 4 mgykg 2 10 mb cn 1 MO 3Wk kg 9 EE 2 5 M n 2 amp 0 i 0 HEM n 2 A amp PM n 2 e eT 0 0 12 24 36 48 60 12 10 th 3 3 14 20 9 mgkg 1 2 8 mgkg 1 2 6 Ca AUC 7 32 2 32 19 6 ugmL S1 1 14 2 gt 177 pg h mL CYP2C19 Cs ug mL AUC pg h mL EM 8 3 32 2 32 8 31 36 0 14 2 70 0 HEM 10 8 12 4 62
239. 1 1 8 15 22 29 57 85 113 141 169 Cmax Tmax AUCo 1egdays Tu ng mL b ng h mL hb 4 65 0 97 1 00 799 5 178 8 927 2 320 7 0 92 1 03 Tmax 22 5mg 24 1 2 22 5mg 20mg nd mt 9 1 10 1 8 15 22 29 57 85 113 141 169 Cmax Tmax AUCo iesaay ng mL ng h mL 20 1 0 0 97 S60 9 190 3 894 9 277 7 0 77 1 40 Tmax
240. dsDNA 2 dsDNA i Ng CA 10 Ml a OE 2 en AA
241. 003 L20040707053 6 HIV P450 virro L20050310041 7 CYP3A44 PF430 zo L20050310042 8 Romero A J et al Clin Pharmaco Ther 71 4 226 2002 L20040707176 9 L20050310043 10 Purkins L et al Br J Clin Pharmacol 56 Suppl 1 24 2003 L20040707054 11 L20050310044 12 P450 m vitro L20050310045 13 Saar T l et al Eur J Clin Pharmacol 63 10 941 2007 IL20071002034 14 Saan T L et al Br J Clin Pharmacol 63 1 116 2007 L20070313251 15 Hagelberg N M et al Eur J Clin Pharmacol 65 3 263 2009 L20090225001 16 Saari TIet al Eur J Clin Pharmacol 64 1 25 2008 L20080117022 17 Hynninen VVet al Antimicrob Agents Chemother 50 6 1967 2006 L20060606012 18 Hynninen V V et al Fundam Clin Pharmacol 21 6 651 2007 L20071203097 19
242. 1 2 3 38 17 44 79 ALT GPT AST GOT 2 5 39 1 0 1 1 2 3 4 5 CK CPK
243. 1 2 3 5 10 70 0 14 20 54 59 6 11 2 1 17 5 9 95 79 202 211 92 69 214 231 95 3 1 3 7 3 10 86 178 206 81 181 224
244. 12 36 4 23 0 103 PM 2 15 7 12 6 19 6 127 5 91 8 177 20 7 32 2 32 19 6 51 1 14 2 177 1 12 15 30 kg 2 6mgkg 1 2 4mgkg 1 2 6 CYP2C19 EM CYP2C19 1 1 CYP2C19 1 17 HEM CYP2C19 1 2 CYP2C19 1 3 PM CYP2C19 4227 2 CYP2C19 2 3 CYP2C19 3 3 2 96 100 3 4 6 L kg 1 0
245. 241 lmsa DX MRSA MRSA 1
246. 4 3 8 muto HMG CoA 3 0 th i AUC CYP3A4 CYP2C1l9 0 JE a 1 2 Rn rE gt C g 1 2 AUC 1 5 CYP3A4 CYP2C9 4 QT 1 0
247. 60606012 18 Hynninen V Vet al Fundam Clin Pharmacol 21 6 651 2007 L20071203097 19 L20070113007 20 Rengelshausen Jet al Clin Pharmacol Ther 78 1 25 2005 L20050812016 21 IL20041124004 22 HSCT GFT L20150615074 23 SCT FI L20150615075 24 L20150615076 25 yo L20050310046 26 yjyo L20050310047 27 L20050310048 28
248. 9 31 Cmax AUC 2 CYP3A4 4 1 200mg 1 2 3 1 300mg 1 2 1 600mg 3 628 323 8 909 106 2 92 ALT GPT 47 1 30 AST GOT 45 1 24 26 0 72 1 400mg
249. DNA 12 13 TNF TNF 14
250. GOT ALT GPT 9 Toxic Epidermal Necrolysis TEN Stevens Johnson 10 i i 11 12
251. T GPT 9 4 AST GOT 7 2 LDH 6 6 6 3 5 2 y GTP 5 1 3 780 3 128 4 19 9 2 9 1 5 6 5 6 gt 7 322 1 830 24 6 3 6 2 5 2 5 1 7 1 6 764 172 22 5 3 9 2 5 1 7 1 4 1 2
252. TNFe 1 04X10 M 12 TNF ce IL 6 IgG1 Fc CDC ADCC TNF a TNF c TNE TNF c TNFo CAM 1 VCAM 1 ke 2 TNFe infliximab genetical recombination 1 IgG1 TNF c 1 328 149000 100 100mgX1 1 Westhovens R et al Arthritis Rheum 2006 54 4 1073 1086 2 Asakura H et al J Gastroenter
253. ol Hepatol 2001 16 7 763 769 3 Targan S R et al N Engl J Med 1997 337 15 1029 1035 4 Hanauer S B et al Lancet 2002 359 1541 1549 5 Present D H et al N Engl J Med 1999 340 18 1398 1405 6 Sands B E et al N Engl J Med 2004 350 9 876 885 7 Lipsky P E et al N Engl J Med 2000 343 22 1594 1602 8 Antoni C et al Ann Rheum Dis 2005 64 8 1150 1157 9 van der Heijde D et al Arthritis Rheum 2007 56 8 2698 2707 10 van der Heijde D et al Arthritis Rheum 2005 52 2 582 591 11 Rutgeerts P et al N Engl J Med 2005 353 23 2462 2476 12 Scallon B J et al Cytokine 1995 7 3 251 259 13 Siegel S A et al Cytokine 1995 7 1 15 23 541 8505 3 2 10 0120 753 280 Janssen Biotech Inc 3 2 10 1 100mL 200mg 1 400mg 1 2 1
254. tJ R_et al Clm Infect Dis 36 9 1122 2003 L20040707126 42 L20050310058 43 yyo m vimo L20041124003 44 yjyo L20050310059 45 vivo L20050310060 46 vivo L20050310061 47 Candida vive L20030310062 48 Candida yyo L20050310063 49 Candida non albicans yo L20050310064 0 Cryptococc
255. us vivo L20050310065 51 Cryptococcus 7z vive L20050310066 52 yo L20050310067 33 m yo L20050310068 34 vo L20050310069 151 8589 3 22 7 0120 664 467 FAX 03 3379 3053 3 22 7 201 ee pe 2800m i VFENDE Dry Syrup 2800mg
256. usion reaction infusion reaction 8 3 8 4 TNF
Download Pdf Manuals
Related Search